Buchumschlag

Cellular immunotherapy in B-cell malignancy

In recent years, cellular immunotherapy in B-cell malignancies has been driven by adoptive transfer of genetically engineered T cells expressing chimeric antigen receptors (CARs). CARs consist of a single chain variable fragment (scFv) of a monoclonal antibody, a spacer domain, a transmembrane domai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schwarzbich, Mark-Alexander (VerfasserIn) , Witzens-Harig, Mathias (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: October 20, 2017
In: Oncology research and treatment
Year: 2017, Jahrgang: 40, Heft: 11, Pages: 674-681
ISSN:2296-5262
DOI:10.1159/000481946
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1159/000481946
Verlag, Volltext: https://www.karger.com/Article/FullText/481946
Volltext
Verfasserangaben:Mark-Alexander Schwarzbich, Mathias Witzens-Harig

MARC

LEADER 00000caa a22000002c 4500
001 1576111156
003 DE-627
005 20220814154226.0
007 cr uuu---uuuuu
008 180606s2017 xx |||||o 00| ||eng c
024 7 |a 10.1159/000481946  |2 doi 
035 |a (DE-627)1576111156 
035 |a (DE-576)506111156 
035 |a (DE-599)BSZ506111156 
035 |a (OCoLC)1341011137 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schwarzbich, Mark-Alexander  |d 1983-  |e VerfasserIn  |0 (DE-588)143268236  |0 (DE-627)64435867X  |0 (DE-576)335999263  |4 aut 
245 1 0 |a Cellular immunotherapy in B-cell malignancy  |c Mark-Alexander Schwarzbich, Mathias Witzens-Harig 
264 1 |c October 20, 2017 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.06.2018 
520 |a In recent years, cellular immunotherapy in B-cell malignancies has been driven by adoptive transfer of genetically engineered T cells expressing chimeric antigen receptors (CARs). CARs consist of a single chain variable fragment (scFv) of a monoclonal antibody, a spacer domain, a transmembrane domain, an intracellular signaling domain, and additional costimulatory domains. The bulk of clinical data available is on CD19-targeting CAR T cells for the treatment of B-cell acute lymphocytic leukemia (B-ALL), chronic lymphocytic leukemia, and B-cell non-Hodgkin lymphoma. Results so far have been promising with impressive rates and depth of remission especially among B-ALL patients. However, CAR T-cell therapy is a complex multi-step process, and clinical trials so far differ profoundly in CAR construct used, gene transfer method, composition of the cellular product, lymphodepletion, and CAR T-cell dose used. Randomized trials will be needed to conclusively evaluate the implications of these differences. The treatment concept is associated with significant neurotoxicity and potentially lethal cytokine release syndrome, both of which require specific management. Improvements in CAR design may help to overcome toxicity, the effects of an immunosuppressive microenvironment, and tumor escape by development of antigen-negative clones. This review will explain the mechanism of action, summarize the clinical experience with this treatment modality so far, and explore future developments in the field. 
700 1 |a Witzens-Harig, Mathias  |e VerfasserIn  |0 (DE-588)1050736516  |0 (DE-627)784812322  |0 (DE-576)404988970  |4 aut 
773 0 8 |i Enthalten in  |t Oncology research and treatment  |d Basel : Karger, 2014  |g 40(2017), 11, Seite 674-681  |h Online-Ressource  |w (DE-627)776629611  |w (DE-600)2749752-5  |w (DE-576)400081660  |x 2296-5262  |7 nnas  |a Cellular immunotherapy in B-cell malignancy 
773 1 8 |g volume:40  |g year:2017  |g number:11  |g pages:674-681  |g extent:8  |a Cellular immunotherapy in B-cell malignancy 
856 4 0 |u http://dx.doi.org/10.1159/000481946  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.karger.com/Article/FullText/481946  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180606 
993 |a Article 
994 |a 2017 
998 |g 1050736516  |a Witzens-Harig, Mathias  |m 1050736516:Witzens-Harig, Mathias  |d 910000  |d 910100  |e 910000PW1050736516  |e 910100PW1050736516  |k 0/910000/  |k 1/910000/910100/  |p 2  |y j 
998 |g 143268236  |a Schwarzbich, Mark-Alexander  |m 143268236:Schwarzbich, Mark-Alexander  |d 910000  |d 910100  |e 910000PS143268236  |e 910100PS143268236  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1576111156  |e 3011776288 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"recId":"1576111156","note":["Gesehen am 06.06.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"roleDisplay":"VerfasserIn","display":"Schwarzbich, Mark-Alexander","role":"aut","family":"Schwarzbich","given":"Mark-Alexander"},{"display":"Witzens-Harig, Mathias","roleDisplay":"VerfasserIn","role":"aut","family":"Witzens-Harig","given":"Mathias"}],"title":[{"title":"Cellular immunotherapy in B-cell malignancy","title_sort":"Cellular immunotherapy in B-cell malignancy"}],"relHost":[{"title":[{"title_sort":"Oncology research and treatment","title":"Oncology research and treatment"}],"recId":"776629611","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 15.12.2023"],"disp":"Cellular immunotherapy in B-cell malignancyOncology research and treatment","part":{"issue":"11","pages":"674-681","year":"2017","extent":"8","text":"40(2017), 11, Seite 674-681","volume":"40"},"pubHistory":["37.2014 -"],"id":{"issn":["2296-5262"],"zdb":["2749752-5"],"eki":["776629611"]},"origin":[{"publisherPlace":"Basel","publisher":"Karger","dateIssuedKey":"2014","dateIssuedDisp":"2014-"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Mark-Alexander Schwarzbich, Mathias Witzens-Harig"]},"id":{"doi":["10.1159/000481946"],"eki":["1576111156"]},"origin":[{"dateIssuedDisp":"October 20, 2017","dateIssuedKey":"2017"}]} 
SRT |a SCHWARZBICCELLULARIM2020 

Ähnliche Einträge